The Liver Forum

Our latest, 'Attribution of NASH as Etiology of Cirrhosis for Clinical Trials Eligibility' in latest issue of @AGA_Gastro - 👏👏👏 congratulations to authors and all working group members! authors.elsevier.com/c/1bbMP3mEmVHES

New Positions Open! forumresearch.org/aboutcontact/e…

October is Liver Awareness Month. Join us TODAY starting at 3:45 pm ET as FLF joins @MadrigalPharma to ring the @Nasdaq closing bell to increase awareness of the need for more screening & testing to improve diagnosis & staging of #NAFLD #NASH→bit.ly/3uMpRiX #LiverHealth

ELF was just approved as a blood test for fibrosis by @US_FDA and this is an important step in the efforts to develop better tools for diagnosing advanced liver disease and getting away from liver biopsy➡️bit.ly/3yULq1f #NAFLD #NASH #liverhealth #patientadvocacy #blog

ELF by @Siemens has been approved by the FDA as a prognostic maker to be used in #NASH. #livertwitter 👇🏼@AlkhouriNaim @schattenbergJ @KathleenCoreyMD @DrLoomba @DrMTLong @RomaLevy @NASH_and_coffee @AASLDtweets @drmoutaz @HD3vedi @surfing_NASH

Ani Kardashian on food insecurity & assoc w/all-cause mortality in US adults w/ #NAFLD #ILC2021: food insecurity is ltd or uncertain availability of nutritionally adequate foods or inability to acquire foods in socially acceptable way. 35 million (18 million in USA) experience it

@AniKardashianMD Food insecurity in adults with NAFLD associated with all-cause mortality after adjustment for a number of factors #ILC2021

Join us today at #ILC2021 for a live webinar with Prof. Boursier and Prof. Noureddin on #FibroScan-based Scores: Agile 3+, Agile 4, Fast™, to identify early and accurately patients at risk of developing cirrhosis and liver-related complications. bit.ly/3gTRHn5 #NAFLD

June 10th is International #NASHDay. Join advocates & partners from across the🌐as we spread awareness about this serious #liverdisease that is on the rise. Together we can make our voices heard! Join the conversation🙌#NASHDay⮕bit.ly/3xpNaPV #NAFLD #NASH @GlobalLiver

I don't know that this is news really but I was one of the patient advocates interviewed for an extensive article in @PharmaVOICE about the need for industry to include patients in the process of drug development⮕bit.ly/3h5wWq5 #NASH #NAFLD #PatientAdvocacy

Nonalcoholic fatty liver disease (#NAFLD) is the most common #ChronicLiverDisease (#CLD) in children worldwide. Our very own Dr. Veronica Miller & the @LiverForum Pediatric Working Group explore research for a “silver bullet” treatment. bit.ly/3tH4P3j

A new paper from BPH's Dr. Veronica Miller & the @LiverForum Pediatric Working Group combs through the research for a “silver bullet” treatment for nonalcoholic fatty liver disease (#NAFLD), the most common #ChronicLiverDisease in children worldwide. publichealth.berkeley.edu/news-media/fea…

Today is #WorldCancerDay, 4 Feb. Did you know? #Livercancer is the 3rd-leading cause of cancer-related deaths🌐worldwide. What are the main causes of liver cancer? ➡️bit.ly/LC-infographic To find out more, consult our new infographic, Liver Cancer Explained. @EASLedu

INDUSTRY STAKEHOLDERS: Get email updates from the CDER Small Business and Industry Assistance (SBIA) program to learn about: 🟠 Industry news 🟠 New guidances 🟠 Meetings & conferences 🟠 Educational tutorials 🟠 Webinars 🟠 And more! Sign up here: ow.ly/fq0R50D1AnG

The Translational Science Interagency Fellowship sponsored by FDA & @ncats_nih_gov is looking for individuals interested in bringing safe & effective drugs, regimens, and devices from the bench to the bedside as quickly as possible. Apply now: go.usa.gov/x7kFj

We are hiring! Know anyone with a background in project management, research, & liver disease? Share our job announcement: bit.ly/3pfAaIy

Don't miss this #webcast on January 29th as the @US_FDA will provide a summary of the agency's current thinking on the published draft guidance📄 & regulatory pathways for development of drugs for treatment of #NASH👉bit.ly/38c7GIt

Learn about FDA’s table of surrogate endpoints that provides transparency, coherency, and consistency for stakeholders seeking to design effective drug development programs in the latest #CDERImpactStory: go.usa.gov/xAan9

Today we’re launching the International Liver Congress™ 2021 easl.eu/ilc2021 Clear your agendas for Wed to Sat, 23–26 June. Prepare to send in your abstracts & register for #EASL’s flagship #ILC2021 on beating liver disease together. Share this with your peers! @EASLedu

DATES HAVE CHANGED! Register for #NASHTAG 2021 today. nash-tag.org